- Home
- ALT vs CLLS Comparison
ALT vs CLLS Comparison
Compare ALT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | CLLS |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 384.3M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALT | CLLS |
|---|---|---|
| Price | $2.96 | $3.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $17.67 | $8.33 |
| AVG Volume (30 Days) | ★ 3.4M | 32.2K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.80 | $1.33 |
| 52 Week High | $7.73 | $5.48 |
Technical Indicators
Market Signals| Indicator | ALT | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 52.47 |
| Support Level | $2.87 | $3.39 |
| Resistance Level | $4.25 | $4.48 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 17.86 | 46.35 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.